EuroBiotech: More Articles of Note

The resignation of Peter Fellner has raised doubts about Ablynx’s united front against Novo Nordisk’s takeover bid. (NS Newsflash/CC BY 2.0)

> The resignation of Peter Fellner raised doubts about Ablynx’s united front against Novo Nordisk’s takeover bid. Fellner quit as chairman with immediate effect on the day Novo went public with its takeover attempt. Release

> Storm Therapeutics added £4 million ($5 million) to its series A round. The VC wing of Taiho Pharmaceutical put up the cash. Statement

> Galapagos and ProQR entered into a fibrosis research collaboration. Release

> Cytovation raised an additional NOK 10 million ($1 million). The financing, which follows the raising of NOK 20 million, will support a phase 1/2a cutaneous warts trial. Statement

> Cypralis secured exclusive rights to certain macrocyclic inhibitors outside of oncology and virology. The inhibitors resulted from a research collaboration between Gilead and Selcia. Release

> Innate Pharma named Eric Vivier as its CSO. Statement